JP2000512651A5 - - Google Patents

Download PDF

Info

Publication number
JP2000512651A5
JP2000512651A5 JP1998502316A JP50231698A JP2000512651A5 JP 2000512651 A5 JP2000512651 A5 JP 2000512651A5 JP 1998502316 A JP1998502316 A JP 1998502316A JP 50231698 A JP50231698 A JP 50231698A JP 2000512651 A5 JP2000512651 A5 JP 2000512651A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998502316A
Other languages
English (en)
Japanese (ja)
Other versions
JP4225571B2 (ja
JP2000512651A (ja
Filing date
Publication date
Priority claimed from DE19624704A external-priority patent/DE19624704A1/de
Application filed filed Critical
Publication of JP2000512651A publication Critical patent/JP2000512651A/ja
Publication of JP2000512651A5 publication Critical patent/JP2000512651A5/ja
Application granted granted Critical
Publication of JP4225571B2 publication Critical patent/JP4225571B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50231698A 1996-06-20 1997-06-20 細胞増殖抑制剤および免疫抑制剤としての新規なピリジルアルカン酸アミド類 Expired - Fee Related JP4225571B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19624704.7 1996-06-20
DE19624704A DE19624704A1 (de) 1996-06-20 1996-06-20 Neue Pyridylalkansäureamide
PCT/EP1997/003243 WO1997048695A1 (en) 1996-06-20 1997-06-20 New pyridyl alkane acid amides as cytostatics and immunosuppressives

Publications (3)

Publication Number Publication Date
JP2000512651A JP2000512651A (ja) 2000-09-26
JP2000512651A5 true JP2000512651A5 (cg-RX-API-DMAC7.html) 2005-02-10
JP4225571B2 JP4225571B2 (ja) 2009-02-18

Family

ID=7797525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50231698A Expired - Fee Related JP4225571B2 (ja) 1996-06-20 1997-06-20 細胞増殖抑制剤および免疫抑制剤としての新規なピリジルアルカン酸アミド類

Country Status (11)

Country Link
US (3) US6444823B1 (cg-RX-API-DMAC7.html)
EP (1) EP0934309B1 (cg-RX-API-DMAC7.html)
JP (1) JP4225571B2 (cg-RX-API-DMAC7.html)
AT (1) ATE223912T1 (cg-RX-API-DMAC7.html)
AU (1) AU3342097A (cg-RX-API-DMAC7.html)
DE (2) DE19624704A1 (cg-RX-API-DMAC7.html)
DK (1) DK0934309T3 (cg-RX-API-DMAC7.html)
ES (1) ES2178779T3 (cg-RX-API-DMAC7.html)
PT (1) PT934309E (cg-RX-API-DMAC7.html)
WO (1) WO1997048695A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA975439B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624704A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
DE19908483A1 (de) * 1999-02-26 2000-10-05 Klinge Co Chem Pharm Fab Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
US6172040B1 (en) * 1999-05-28 2001-01-09 A. Satyanarayan Naidu Immobilized lactoferrin antimicrobial agents and the use thereof
BR0114323A (pt) 2000-09-29 2003-07-01 Glaxo Group Ltd Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
AU2006224295A1 (en) 2005-03-17 2006-09-21 Pfizer, Inc. N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
EP1978963A2 (en) * 2006-01-17 2008-10-15 Merck & Co., Inc. 2,5 diaza-bicycloý2.2.1¨heptane derivatives as calcium channel blockers
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
WO2010023307A1 (en) 2008-08-29 2010-03-04 Topotarget A/S Novel urea and thiourea derivatives
WO2010114907A1 (en) * 2009-03-31 2010-10-07 Vanderbilt University Sulfonyl-azetidin-3-yl-methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
PH12013500412A1 (en) 2010-09-03 2013-04-22 Forma Tm Llc Novel compounds and compositions for the inhibition of nampt
TW201216963A (en) 2010-09-03 2012-05-01 Forma Therapeutics Inc Novel compounds and compositions for the inhibition of NAMPT
RU2016116533A (ru) 2010-09-03 2018-11-30 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
RU2616612C2 (ru) 2011-05-04 2017-04-18 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
RU2617643C2 (ru) 2011-05-09 2017-04-25 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
CN109776494B (zh) * 2018-12-25 2021-06-18 中国人民解放军第二军医大学 一种多靶点抗肿瘤活性的烟酰胺磷酸核糖转移酶氮芥类抑制剂及其制备与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283541A (en) 1980-05-27 1981-08-11 Usv Pharmaceutical Corporation Pyridylacyl-hydroxamates
NL8005133A (nl) * 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
JPS57136518A (en) * 1981-02-18 1982-08-23 Eisai Co Ltd Immunoregulator
US5326772A (en) * 1984-09-28 1994-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Diaryl compounds for their use
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
DE3641822A1 (de) * 1986-12-06 1988-06-16 Goedecke Ag Verwendung von dihydrophenylaminosaeurederivaten und diese enthaltende arzneimittel zur immunmodulation und cytostase
JPS63179869A (ja) * 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd ピペリジン誘導体
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
WO1989007443A1 (fr) 1988-02-19 1989-08-24 Byk Gulden Lomberg Chemische Fabrik Gmbh R-(-)-niguldipine optiquement pure et ses derives pour traiter des affections tumorales
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
IE903196A1 (en) * 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
AU7652391A (en) * 1990-04-10 1991-10-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridine esters
CA2080127A1 (en) * 1990-04-10 1991-10-11 Peter Zimmermann Pyridines as medicaments
US5260323A (en) * 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
DE4020570A1 (de) * 1990-06-28 1992-01-02 Hoechst Ag 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung
US5244908A (en) * 1990-07-30 1993-09-14 Takeda Chemical Industries, Ltd. Imidazopyridine derivatives and their pharmaceutical use
US5229400A (en) * 1990-10-05 1993-07-20 Ajinomoto Co., Inc. Piperidine compounds and their use as antiarrhythmic agents
FR2676053B1 (fr) * 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE69209576D1 (de) * 1991-05-10 1996-05-09 Takeda Chemical Industries Ltd Pyridinderivate, deren Herstellung und Anwendung
US5208247A (en) 1991-08-01 1993-05-04 American Cyanamid Company Pyridinium compounds which are useful as antagonists of platelet activating factor
EP0548883A1 (de) * 1991-12-24 1993-06-30 Hoechst Aktiengesellschaft Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US5622976A (en) 1991-12-31 1997-04-22 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
ZA947969B (en) 1993-10-15 1996-07-12 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
AU698313B2 (en) 1994-03-14 1998-10-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
FR2738245B1 (fr) * 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
DE19624704A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
US6451816B1 (en) * 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC7.html)
JP2000501771A5 (cg-RX-API-DMAC7.html)
JP2000511368A5 (cg-RX-API-DMAC7.html)
JP2000501599A5 (cg-RX-API-DMAC7.html)
JP2000509213A5 (cg-RX-API-DMAC7.html)
JP2000501018A5 (cg-RX-API-DMAC7.html)
JP2002513303A5 (cg-RX-API-DMAC7.html)
JP2000507909A5 (cg-RX-API-DMAC7.html)
JP2000501324A5 (cg-RX-API-DMAC7.html)
JP2001501379A5 (cg-RX-API-DMAC7.html)
JP2000501825A5 (cg-RX-API-DMAC7.html)
JP2000501338A5 (cg-RX-API-DMAC7.html)
JP2002513288A5 (cg-RX-API-DMAC7.html)
JP2000500874A5 (cg-RX-API-DMAC7.html)
JP2002514301A5 (cg-RX-API-DMAC7.html)
JP2001501132A5 (cg-RX-API-DMAC7.html)
JP2000507578A5 (cg-RX-API-DMAC7.html)
JP2000502568A5 (cg-RX-API-DMAC7.html)
JP2000501774A5 (cg-RX-API-DMAC7.html)
JP2000500912A5 (cg-RX-API-DMAC7.html)
JP2001506118A5 (cg-RX-API-DMAC7.html)
JP2000502570A5 (cg-RX-API-DMAC7.html)
JP2000514963A5 (cg-RX-API-DMAC7.html)
JP2000501876A5 (cg-RX-API-DMAC7.html)
JP2000501744A5 (cg-RX-API-DMAC7.html)